|
Gene: AGT |
Gene summary for AGT |
Gene summary. |
Gene information | Species | Human | Gene symbol | AGT | Gene ID | 183 |
Gene name | angiotensinogen | |
Gene Alias | ANHU | |
Cytomap | 1q42.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B0ZBE2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
183 | AGT | NAFLD1 | Human | Liver | NAFLD | 4.58e-03 | -3.05e-01 | -0.04 |
183 | AGT | S42 | Human | Liver | HCC | 2.40e-02 | -4.14e-01 | -0.0103 |
183 | AGT | S43 | Human | Liver | Cirrhotic | 7.79e-28 | -1.08e-01 | -0.0187 |
183 | AGT | HCC1_Meng | Human | Liver | HCC | 2.73e-41 | 6.72e-01 | 0.0246 |
183 | AGT | HCC2_Meng | Human | Liver | HCC | 8.23e-41 | -9.86e-01 | 0.0107 |
183 | AGT | cirrhotic1 | Human | Liver | Cirrhotic | 5.97e-29 | 6.14e-01 | 0.0202 |
183 | AGT | cirrhotic2 | Human | Liver | Cirrhotic | 2.37e-20 | 4.13e-01 | 0.0201 |
183 | AGT | HCC1 | Human | Liver | HCC | 1.03e-25 | 5.85e+00 | 0.5336 |
183 | AGT | HCC2 | Human | Liver | HCC | 2.33e-29 | 5.83e+00 | 0.5341 |
183 | AGT | HCC5 | Human | Liver | HCC | 3.96e-03 | 1.91e+00 | 0.4932 |
183 | AGT | Pt13.a | Human | Liver | HCC | 1.99e-03 | 2.09e-01 | 0.021 |
183 | AGT | Pt13.b | Human | Liver | HCC | 2.28e-26 | 1.73e-01 | 0.0251 |
183 | AGT | Pt14.a | Human | Liver | HCC | 1.54e-04 | 2.14e-01 | 0.0169 |
183 | AGT | Pt14.b | Human | Liver | HCC | 9.40e-11 | 2.22e-01 | 0.018 |
183 | AGT | S014 | Human | Liver | HCC | 8.01e-36 | 4.30e+00 | 0.2254 |
183 | AGT | S015 | Human | Liver | HCC | 3.00e-44 | 4.72e+00 | 0.2375 |
183 | AGT | S016 | Human | Liver | HCC | 9.89e-43 | 4.70e+00 | 0.2243 |
183 | AGT | S027 | Human | Liver | HCC | 1.95e-20 | 2.60e+00 | 0.2446 |
183 | AGT | S028 | Human | Liver | HCC | 3.71e-33 | 2.88e+00 | 0.2503 |
183 | AGT | S029 | Human | Liver | HCC | 9.24e-41 | 3.24e+00 | 0.2581 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007048220 | Esophagus | HGIN | response to oxygen levels | 76/2587 | 347/18723 | 2.36e-05 | 6.25e-04 | 76 |
GO:003629320 | Esophagus | HGIN | response to decreased oxygen levels | 70/2587 | 322/18723 | 6.23e-05 | 1.44e-03 | 70 |
GO:000166620 | Esophagus | HGIN | response to hypoxia | 67/2587 | 307/18723 | 7.82e-05 | 1.75e-03 | 67 |
GO:004343420 | Esophagus | HGIN | response to peptide hormone | 79/2587 | 414/18723 | 1.60e-03 | 1.79e-02 | 79 |
GO:190165318 | Esophagus | HGIN | cellular response to peptide | 68/2587 | 359/18723 | 3.88e-03 | 3.54e-02 | 68 |
GO:00064876 | Esophagus | HGIN | protein N-linked glycosylation | 17/2587 | 65/18723 | 6.04e-03 | 4.87e-02 | 17 |
GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
GO:0001666111 | Esophagus | ESCC | response to hypoxia | 192/8552 | 307/18723 | 1.59e-09 | 3.69e-08 | 192 |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
GO:00181969 | Esophagus | ESCC | peptidyl-asparagine modification | 22/8552 | 24/18723 | 2.82e-06 | 3.21e-05 | 22 |
GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00182799 | Esophagus | ESCC | protein N-linked glycosylation via asparagine | 21/8552 | 23/18723 | 5.69e-06 | 5.90e-05 | 21 |
GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
hsa0541515 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
AGT | AGTR1 | AGT_AGTR1B | AGT | Esophagus | ESCC |
AGT | AGTR1 | AGT_AGTR1B | AGT | HNSCC | ADJ |
AGT | AGTR1 | AGT_AGTR1B | AGT | Liver | Healthy |
AGT | AGTR1 | AGT_AGTR1B | AGT | Liver | Precancer |
AGT | AGTR1 | AGT_AGTR1B | AGT | THCA | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AGT | SNV | Missense_Mutation | c.1282N>G | p.Ile428Val | p.I428V | P01019 | protein_coding | tolerated(1) | benign(0.003) | TCGA-55-8207-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
AGT | SNV | Missense_Mutation | novel | c.932N>A | p.Pro311His | p.P311H | P01019 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AGT | SNV | Missense_Mutation | novel | c.537N>T | p.Lys179Asn | p.K179N | P01019 | protein_coding | tolerated(0.06) | probably_damaging(0.932) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
AGT | SNV | Missense_Mutation | novel | c.1022N>T | p.Cys341Phe | p.C341F | P01019 | protein_coding | tolerated(0.62) | benign(0.023) | TCGA-22-4594-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AGT | SNV | Missense_Mutation | c.667N>C | p.Phe223Leu | p.F223L | P01019 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-34-5231-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
AGT | SNV | Missense_Mutation | rs761670478 | c.103C>T | p.Arg35Trp | p.R35W | P01019 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-92-8064-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
AGT | SNV | Missense_Mutation | novel | c.728N>G | p.Glu243Gly | p.E243G | P01019 | protein_coding | deleterious(0.01) | benign(0) | TCGA-NC-A5HL-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AGT | insertion | Nonsense_Mutation | novel | c.560_576dupTACAGGGCCTGCTAGTG | p.Ala193TyrfsTer5 | p.A193Yfs*5 | P01019 | protein_coding | TCGA-NK-A5CT-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
AGT | SNV | Missense_Mutation | novel | c.1261N>C | p.Val421Leu | p.V421L | P01019 | protein_coding | tolerated(0.12) | benign(0.11) | TCGA-CN-6020-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
AGT | SNV | Missense_Mutation | novel | c.526N>A | p.Asp176Asn | p.D176N | P01019 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-CV-6938-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | QUINAPRIL | QUINAPRIL | 12693379,11849656 | |
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | chlorthalidone | CHLORTHALIDONE | ||
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | CYCLOSPORIN A | 10642325 | ||
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | ADENOVIRUS VECTOR | 16014023 | ||
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | Antiinflammatory agents, non-steroids | 20538124 | ||
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | CORTISOL | HYDROCORTISONE | 15576665 | |
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | Ace Inhibitors, Plain | 14643574 | ||
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | atenolol | ATENOLOL | 11593098,14700505 | |
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | irbesartan | IRBESARTAN | 11593098,15614026,14700505 | |
183 | AGT | ENZYME, DRUGGABLE GENOME, PROTEASE INHIBITOR, G PROTEIN COUPLED RECEPTOR, HORMONE ACTIVITY, GROWTH FACTOR | ANTI-ANGIOGENIC AGENTS | 15578913 |
Page: 1 2 3 |